Skip to main content
GL Pharm Tech Corp. logo

GL Pharm Tech Corp. — Investor Relations & Filings

Ticker · 204840 ISIN · KR7204840003 KO Manufacturing
Open in API
Filings indexed 260 across all filing types
Latest filing 2023-10-10 Major Shareholding Noti…
Country KR South Korea
Listing KO 204840

About GL Pharm Tech Corp.

http://www.glpt.co.kr/

GL Pharm Tech Corp. is a pharmaceutical company specializing in the development of incrementally modified drugs (IMDs). The company focuses on creating improved versions of existing pharmaceutical products by utilizing advanced drug formulation and delivery technologies. Its core mission is to enhance the therapeutic value and safety of marketed drugs, with a specific emphasis on reducing side effects and improving patient convenience. GL Pharm Tech is actively engaged in research and development, managing a pipeline of drug candidates and conducting clinical trials to support the commercialization of its enhanced pharmaceutical products.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Services Commission and the Korea Exchange. This type of filing is a regulatory requirement for entities that cross specific ownership thresholds in a company. In the provided taxonomy, this falls under 'Major Shareholding Notification' (MRQ), which covers notifications of changes in significant share ownership levels.
2023-10-10 Korean
투자판단관련주요경영사항(최대주주 변경을 수반하는 주식매매계약을 위한 양해각서(MOU) 체결)
M&A Activity Classification · 1% confidence The document is a regulatory filing from a Korean company (GL PharmTech) announcing the signing of a Memorandum of Understanding (MOU) regarding a change in the company's largest shareholder through a stock purchase agreement. This type of corporate event, involving M&A-related negotiations and changes in control, falls under the category of M&A Activity (TAR).
2023-09-14 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) from a Korean company, GL PharmTech, detailing a decision to issue new shares through a third-party allocation (유상증자결정). This type of filing is a formal announcement of a capital change and share issuance, which falls under the 'Share Issue/Capital Change' category.
2023-09-14 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-Annual Report) for the company '지엘팜텍' (GL PharmTech) covering the period from January 1, 2023, to June 30, 2023. It contains detailed financial information, business operations, management discussions, and corporate governance details, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2023
2023-08-11 Korean
[기재정정]사업보고서 (2022.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) which is the Korean equivalent of an Annual Report (10-K). It contains detailed financial information, management discussion, business operations, and audit information for the fiscal year 2022. The document explicitly mentions it is a 'Correction Report' (정정신고) for the previously submitted Annual Report, which is a standard procedure for 10-K filings in the Korean market. FY 2022
2023-07-28 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'GL PharmTech' (지엘팜텍) covering the period from January 1, 2023, to March 31, 2023. It contains detailed financial data, business operations, management discussions, and capital structure information. As it is a comprehensive financial report for a period shorter than a full fiscal year, it falls under the 'Interim / Quarterly Report' category. Q1 2023
2023-05-09 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.